Penumbra (PEN) is back in focus after recent trading left the stock around $317.20, prompting investors to reassess its performance over the past month and past 3 months.

Looking beyond the latest move, Penumbra’s 1 year total shareholder return of 23.42% contrasts with a year to date share price return of 2.51%, while the 3 year total shareholder return has declined 6.7%. This suggests that momentum has cooled after stronger recent gains.

If you are assessing how Penumbra fits alongside other healthcare ideas, this is a good moment to scan for additional opportunities in AI focused medical and life sciences stocks via the 41 healthcare AI stocks.

So with Penumbra shares roughly flat year to date after a stronger 1 year run, is the current US$317.20 level an entry point for patient investors, or has the market already priced in the company’s future growth potential?

Most Popular Narrative: 12.7% Undervalued

At a last close of $317.20 against a narrative fair value of about $363.36, Penumbra is framed as undervalued, with that view resting on specific growth and profitability assumptions.

The soon-to-be-released STORM-PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism. A positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.

Curious what kind of revenue expansion, margin lift and future earnings multiple are built into that fair value line? The underlying narrative leans on ambitious growth targets, rising profitability and a rich future P/E to support that $363.36 figure.

Result: Fair Value of $363.36 (UNDERVALUED)

However, Penumbra’s story could change quickly if clinical results disappoint or if competition and pricing pressure reduce the earnings power implied in that US$363.36 fair value.

Another View on Penumbra’s Valuation

The fair value narrative presents Penumbra as about 12.7% undervalued at $317.20. However, the market is already paying a P/E of 72.9x, compared with around 24x for both the US Medical Equipment industry and close peers, and a fair ratio of 28x. That gap points to meaningful valuation risk if sentiment cools.

For a closer look at how this compares with earnings power and growth expectations, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed tone so far, with optimism around growth but clear valuation questions, it makes sense to review the data yourself and act promptly. To see what positive factors analysts have identified, take a closer look at the 2 key rewards.

Looking for more investment ideas beyond Penumbra?

Do not stop your research with Penumbra alone. Broaden your watchlist with fresh ideas that match your goals using focused stock screeners on Simply Wall St.

• Target potential upside by scanning companies that trade below their estimated worth through the 45 high quality undervalued stocks.
• Prioritize resilience by reviewing the 66 resilient stocks with low risk scores to spot stocks with steadier risk profiles that may better suit your comfort level.
• Hunt for underfollowed opportunities using the screener containing 20 high quality undiscovered gems before they attract wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.